State Street
BEAM icon

State Street’s Beam Therapeutics BEAM Stock Holding History

State Street’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200M Buy
5,827,122
+127,857
+2% +$3.86M 0.01% 1052
2026
Q1 		$136M Buy
5,699,265
+470,736
+9% +$13.1M ﹤0.01% 1192
2025
Q4 		$145M Buy
5,228,529
+1,219,871
+30% +$31.1M ﹤0.01% 1140
2025
Q3 		$97.3M Buy
4,008,658
+370,392
+10% +$7.37M ﹤0.01% 1348
2025
Q2 		$61.9M Buy
3,638,266
+198,147
+6% +$3.45M ﹤0.01% 1572
2025
Q1 		$67.2M Buy
3,440,119
+362,742
+12% +$9.5M ﹤0.01% 1495
2024
Q4 		$76.3M Sell
3,077,377
-852,180
-22% -$21.7M ﹤0.01% 1508
2024
Q3 		$96.3M Buy
3,929,557
+437,402
+13% +$11.3M ﹤0.01% 1347
2024
Q2 		$81.8M Sell
3,492,155
-239,037
-6% -$5.87M ﹤0.01% 1387
2024
Q1 		$123M Sell
3,731,192
-885,166
-19% -$27.6M 0.01% 1173
2023
Q4 		$126M Buy
4,616,358
+474,229
+11% +$11.8M 0.01% 1149
2023
Q3 		$99.6M Buy
4,142,129
+555,125
+15% +$14.9M 0.01% 1188
2023
Q2 		$115M Buy
3,587,004
+350,916
+11% +$11.4M 0.01% 1126
2023
Q1 		$99.1M Buy
3,236,088
+142,177
+5% +$5.61M 0.01% 1193
2022
Q4 		$121M Buy
3,093,911
+531,502
+21% +$23.8M 0.01% 1057
2022
Q3 		$122M Sell
2,562,409
-773,918
-23% -$44.1M 0.01% 996
2022
Q2 		$129M Buy
3,336,327
+1,354,781
+68% +$53.9M 0.01% 999
2022
Q1 		$114M Buy
1,981,546
+298,383
+18% +$19.6M 0.01% 1204
2021
Q4 		$134M Buy
1,683,163
+281,443
+20% +$24.1M 0.01% 1082
2021
Q3 		$122M Buy
1,401,720
+81,345
+6% +$8.17M 0.01% 1113
2021
Q2 		$170M Buy
1,320,375
+102,104
+8% +$8.14M 0.01% 936
2021
Q1 		$97.5M Sell
1,218,271
-212,139
-15% -$20.2M 0.01% 1253
2020
Q4 		$117M Buy
1,430,410
+898,932
+169% +$44.2M 0.01% 1035
2020
Q3 		$13.1M Buy
531,478
+308,179
+138% +$7.65M ﹤0.01% 2293
2020
Q2 		$6.25M Buy
223,299
+33,918
+18% +$731K ﹤0.01% 2652
2020
Q1 		$3.41M Buy
+189,381
New +$4.12M ﹤0.01% 2813

Other funds holding BEAM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street's BEAM Position: Q2 2026 in Review

State Street increased its Beam Therapeutics (BEAM) stake by 2.2% in Q2 2026, buying an estimated $3.86M and bringing the position to 5,827,122 shares worth $200M. The position accounts for 0.01% of the portfolio, ranked #1052.

State Street first reported a position in BEAM in Q1 2020 and has held it in 26 quarters since. 277 funds tracked by Wall St. Rank hold BEAM as of Q2 2026.

  • State Street held 5,827,122 shares of Beam Therapeutics worth $200M as of Q2 2026.
  • State Street bought 127,857 Beam Therapeutics shares in Q2 2026, an estimated $3.86M.
  • Beam Therapeutics made up 0.01% of State Street's portfolio in Q2 2026, its #1052 holding.
  • State Street first reported a position in Beam Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • 277 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.